エドガーで原本を確認する
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF THE
SECURITIES EXCHANGE ACT OF 1934
For the month of January, 2025
Commission File Number: 001-40724
CHINA JO-JO DRUGSTORES, INC.
(Translation of registrant’s name into English)
4th Floor, Building 5, Renxin Yaju, Gong Shu District,
Hangzhou City, Zhejiang Province, People’s Republic of China, 310014
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
China Jo-Jo Drugstores, Inc., a Cayman Islands exempted company (the “Company”) furnishes under the cover of Form 6-K the following interim financial statements:
FOR THE SIX MONTHS ENDED SEPTEMBER 30, 2024
FINANCIAL STATEMENTS
CHINA JO-JO DRUGSTORES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
| September 30, | March 31, | |||||||
| 2024 | 2024 | |||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| CURRENT ASSETS | ||||||||
| Cash and cash equivalents | $ | 18,001,171 | $ | 20,149,806 | ||||
| Restricted cash | 13,091,736 | 12,724,365 | ||||||
| Trade receivable | 16,920,749 | 15,824,103 | ||||||
| Inventories | 18,774,831 | 16,248,373 | ||||||
| Other receivables, net | 2,120,851 | 2,938,049 | ||||||
| Advances to suppliers | 1,062,427 | 914,776 | ||||||
| Due from related parties | 340,981 | 313,346 | ||||||
| Other current assets | 768,898 | 569,544 | ||||||
| Total current assets | 71,081,644 | 69,682,362 | ||||||
| NON-CURRENT ASSETS | ||||||||
| Property and equipment, net | 5,011,986 | 4,906,589 | ||||||
| Long-term investment | 1,229,785 | 1,195,261 | ||||||
| Farmland assets | 652,470 | 634,153 | ||||||
| Long-term deposits | 1,041,305 | 1,119,006 | ||||||
| Other noncurrent assets | 696,720 | 682,437 | ||||||
| Operating lease right-of-use assets | 11,420,641 | 13,827,360 | ||||||
| Intangible assets, net | 3,056,938 | 3,009,922 | ||||||
| Total non-current assets | 23,109,845 | 25,374,728 | ||||||
| Total assets | $ | 94,191,489 | $ | 95,057,090 | ||||
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||
| CURRENT LIABILITIES | ||||||||
| Short-term loan payable | $ | 284,998 | $ | 276,997 | ||||
| Accounts payable | 27,241,130 | 31,630,131 | ||||||
| Notes payable | 32,689,034 | 31,676,335 | ||||||
| Other payables | 1,291,996 | 2,493,482 | ||||||
| Other payables - related parties | 1,986,619 | 1,833,509 | ||||||
| Customer deposits | 474,677 | 518,241 | ||||||
| Taxes payable | 509,234 | 682,239 | ||||||
| Accrued liabilities | 399,728 | 386,395 | ||||||
| Current portion of operating lease liabilities | 2,659,985 | 4,862,766 | ||||||
| Total current liabilities | 67,537,401 | 74,360,095 | ||||||
| Long-term operating lease liabilities | 6,532,936 | 6,403,858 | ||||||
| Total liabilities | 74,070,337 | 80,763,953 | ||||||
| COMMITMENTS AND CONTINGENCIES | ||||||||
| SHAREHOLDERS’ EQUITY | ||||||||
| Ordinary shares; $0.24 par value; 150,000,000 shares authorized; 6,654,077 and 1,743,362 shares issued and outstanding as of September 30, 2024 and March 31, 2024, respectively | 1,596,979 | 418,407 | ||||||
| Preferred shares; $0.001 par value; 10,000,000 shares authorized; none issued and outstanding as of September 30, 2024 and March 31, 2024 | ||||||||
| Additional paid-in capital | 92,868,406 | 86,413,978 | ||||||
| Statutory reserves | 1,309,109 | 1,309,109 | ||||||
| Accumulated deficit | (75,784,338 | ) | (73,507,246 | ) | ||||
| Accumulated other comprehensive income | 1,477,869 | 1,005,762 | ||||||
| Total shareholders’ equity attributed to China Jo-Jo | 21,468,025 | 15,640,010 | ||||||
| Noncontrolling interests | (1,346,873 | ) | (1,346,873 | ) | ||||
| Total shareholders’ equity | 20,121,152 | 14,293,137 | ||||||
| Total liabilities and shareholders’ equity | $ | 94,191,489 | $ | 95,057,090 | ||||
CHINA JO-JO DRUGSTORES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(UNAUDITED)
| For the six months ended September 30, |
||||||||
| 2024 | 2023 | |||||||
| REVENUES, NET | $ | 71,159,724 | $ | 78,574,409 | ||||
| COST OF GOODS SOLD | 56,562,292 | 62,641,320 | ||||||
| GROSS PROFIT | 14,597,432 | 15,933,089 | ||||||
| SELLING EXPENSES | 14,103,893 | 14,044,750 | ||||||
| GENERAL AND ADMINISTRATIVE EXPENSES | 2,716,269 | 1,632,357 | ||||||
| TOTAL OPERATING EXPENSES | 16,820,162 | 15,677,107 | ||||||
| INCOME (LOSS) FROM OPERATIONS | (2,222,730 | ) | 255,982 | |||||
| OTHER INCOME (EXPENSES): | ||||||||
| INTEREST INCOME | 202,938 | 216,891 | ||||||
| INTEREST EXPENSE | (4,471 | ) | (307 | ) | ||||
| INVESTMENT LOSS | (1,642,910 | ) | ||||||
| OTHER INCOME (EXPENSES) | (242,230 | ) | 285,255 | |||||
| TOTAL OTHER INCOME (EXPENSES) | (43,763 | ) | (1,141,071 | ) | ||||
| LOSS BEFORE INCOME TAXES | (2,266,493 | ) | (885,089 | ) | ||||
| PROVISION FOR INCOME TAXES | 10,599 | 39,172 | ||||||
| NET LOSS | (2,277,092 | ) | (924,261 | ) | ||||
| LESS: NET LOSS ATTRIBUTABLE TO NONCONTROLLING INTEREST | (14 | ) | ||||||
| NET LOSS ATTRIBUTABLE TO CHINA JO-JO DRUGSTORES, INC. | (2,277,092 | ) | (924,275 | ) | ||||
| OTHER COMPREHENSIVE LOSS | ||||||||
| FOREIGN CURRENCY TRANSLATION ADJUSTMENTS | 472,107 | (794,542 | ) | |||||
| COMPREHENSIVE LOSS | (1,804,985 | ) | (1,718,803 | ) | ||||
| WEIGHTED AVERAGE NUMBER OF SHARES: | ||||||||
| Basic | 5,378,226 | 1,195,746 | ||||||
| Diluted | 5,378,226 | 1,195,746 | ||||||
| LOSS PER SHARE: | ||||||||
| Basic | $ | (0.42 | ) | $ | (0.77 | ) | ||
| Diluted | $ | (0.42 | ) | $ | (0.77 | ) | ||
CHINA JO-JO DRUGSTORES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY
(UNAUDITED)
| Accumulated | ||||||||||||||||||||||||||||||||
| Ordinary Share | Additional | Retained Earnings | other | Non- | ||||||||||||||||||||||||||||
| Number of | Paid-in | Statutory | Accumulated | comprehensive | controlling | |||||||||||||||||||||||||||
| shares | Amount | capital | reserves | deficit | income/(loss) | interest | Total | |||||||||||||||||||||||||
| BALANCE, March 31, 2023 | 1,184,861 | 284,367 | 83,958,418 | 1,309,109 | (69,273,018 | ) | 1,735,135 | (1,346,859 | ) | 16,667,152 | ||||||||||||||||||||||
| Sale of shares and warrants | 498,000 | 119,520 | 2,470,080 | 2,589,600 | ||||||||||||||||||||||||||||
| Fractional shares issued for reverse stock split | - | |||||||||||||||||||||||||||||||
| Net loss | - | (924,247 | ) | (14 | ) | (924,261 | ) | |||||||||||||||||||||||||
| Foreign currency translation loss | - | (794,542 | ) | (794,542 | ) | |||||||||||||||||||||||||||
| BALANCE, September 30, 2023 | 1,682,861 | 403,887 | 86,428,498 | 1,309,109 | (70,197,265 | ) | 940,593 | (1,346,873 | ) | 17,537,949 | ||||||||||||||||||||||
| BALANCE, March 31, 2024 | 1,743,362 | 418,407 | 86,413,978 | 1,309,109 | (73,507,246 | ) | 1,005,762 | (1,346,873 | ) | 14,293,137 | ||||||||||||||||||||||
| Issuance of incentive ordinary shares award | 420,715 | 100,972 | (100,972 | ) | ||||||||||||||||||||||||||||
| Sale of shares and warrants | 4,490,000 | 1,077,600 | 6,555,400 | 7,633,000 | ||||||||||||||||||||||||||||
| Net loss | - | (2,277,092 | ) | (2,277,092 | ) | |||||||||||||||||||||||||||
| Foreign currency translation loss | - | 472,107 | 472,107 | |||||||||||||||||||||||||||||
| BALANCE, September 30, 2024 | 6,654,077 | 1,596,979 | 92,868,406 | 1,309,109 | (75,784,338 | ) | 1,477,869 | (1,346,873 | ) | 20,121,152 | ||||||||||||||||||||||
CHINA JO-JO DRUGSTORES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
| For the six months ended September 30, |
||||||||
| 2024 | 2023 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net loss | $ | (2,277,092 | ) | $ | (924,261 | ) | ||
| Adjustments to reconcile net loss to net cash provided by operating activities: | ||||||||
| Depreciation and amortization | 500,965 | 320,966 | ||||||
| Amortization of right-of-use assets | 3,317,679 | |||||||
| Loss from disposal of property and equipment | 3,616 | |||||||
| Bad debt direct write-off and provision | (188,407 | ) | (888,847 | ) | ||||
| Amounts due from related parties | (18,047 | ) | ||||||
| Investment loss | 1,642,910 | |||||||
| Change in operating assets and liabilities: | ||||||||
| Accounts receivable | 638,840 | (3,341,534 | ) | |||||
| Notes receivable | 20,051 | |||||||
| Inventories and biological assets | (2,004,377 | ) | (5,302,535 | ) | ||||
| Other receivables | (138,098 | ) | 283,624 | |||||
| Advances to suppliers | (174,699 | ) | (317,550 | ) | ||||
| Other current assets | (178,213 | ) | (174,537 | ) | ||||
| Long term deposit | 107,202 | (113,118 | ) | |||||
| Other noncurrent assets | 5,289 | 18,991 | ||||||
| Accounts payable | (5,164,733 | ) | 9,206,918 | |||||
| Customer deposits | (57,032 | ) | (413 | ) | ||||
| Taxes payable | (187,770 | ) | 51,233 | |||||
| Operating lease liabilities | (2,921,133 | ) | ||||||
| Other payables and accrued liabilities | (1,218,807 | ) | 240,804 | |||||
| Net cash (used in) provided by operating activities | (9,954,817 | ) | 722,702 | |||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
| Acquisition of equipment | (154,473 | ) | (9,294 | ) | ||||
| Purchases of intangible assets | (347 | ) | (27,335 | ) | ||||
| Investment in a joint venture | (1,122,224 | ) | ||||||
| Additions to leasehold improvements | (275,466 | ) | (166,765 | ) | ||||
| Net cash used in investing activities | (430,286 | ) | (1,325,618 | ) | ||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
| Proceeds from notes payable | 31,850,735 | 25,098,414 | ||||||
| Repayment of notes payable | (31,755,498 | ) | (28,184,237 | ) | ||||
| Proceeds from sale of shares and warrants | 7,633,000 | 2,589,600 | ||||||
| Repayment of other payables-related parties | 99,800 | 824,146 | ||||||
| Net cash provided by financing activities | 7,828,037 | 327,923 | ||||||
| EFFECT OF EXCHANGE RATE ON CASH | 775,802 | (1,695,331 | ) | |||||
| (DECREASE) IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH | (1,781,264 | ) | (1,970,324 | ) | ||||
| CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, beginning of period | 32,874,171 | 31,570,644 | ||||||
| CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, end of period | $ | 31,092,907 | $ | 29,600,320 | ||||
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: | ||||||||
| Cash paid for interest | 4,471 | 307 | ||||||
| Cash paid for income taxes | $ | 44,988 | $ | 77,806 | ||||
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
The following management’s discussion and analysis should be read in conjunction with our unaudited condensed consolidated financial statements. In addition to historical information, the following discussion contains certain forward-looking statements within the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements relate to our future plans, objectives, expectations and intentions. These statements may be identified by the use of words such as “may,” “will,” “could,” “expect,” “anticipate,” “intend,” “believe,” “estimate,” “plan,” “predict,” and similar terms or terminology, or the negative of such terms or other comparable terminology. Although we believe the expectations expressed in these forward-looking statements are based on reasonable assumptions within the bound of our knowledge of our business, our actual results could differ materially from those discussed in these statements. Factors that could contribute to such differences include, but are not limited to, those discussed in the “Risk Factors” section of our annual report on Form 20-F for the year ended March 31, 2024 and filed with the SEC on July 30, 2024. We undertake no obligation to update publicly any forward-looking statements for any reason even if new information becomes available or other events occur in the future.
Our financial statements are prepared in U.S. Dollars and in accordance with accounting principles generally accepted in the United States. See “Exchange Rates” below for information concerning the exchanges rates at which Renminbi (“RMB”) were translated into U.S. Dollars (“USD” or “$”) at various pertinent dates and for pertinent periods.
Overview
We currently operate in four business segments in China: (1) retail drugstores, (2) online pharmacy, (3) wholesale of products similar to those that we carry in our pharmacies and (4) farming and selling herbs used for traditional Chinese medicine (“TCM”).
Our drugstores offer customers a wide variety of pharmaceutical products, including prescription and over-the-counter (“OTC”) drugs, nutritional supplements, TCM, personal and family care products, medical devices, and convenience products, including consumable, seasonal, and promotional items. Additionally, we have licensed doctors of both western medicine and TCM on site for consultation, examination and treatment of common ailments at scheduled hours. As of September 30, 2024, we had 132 pharmacies in Hangzhou city under the store brand of “Jiuzhou Grand Pharmacy”.
Since May 2010, we have also been selling certain OTC drugs, medical devices, nutritional supplements and other sundry products online. Starting from 2020, we have been able to sell prescription drugs online. Our online pharmacy sells through several third-party platforms such as Alibaba’s Tmall, JD.com, Amazon.com and the Company’s own platform all over China. Our sales through our own platform are primarily generated by customers who use their private commercial medical insurances packages.
We operate a wholesale business through Zhejiang Jiuxin Medicine Co., Ltd. (“Jiuxin Medicine”) distributing third-party pharmaceutical products (similar to those carried by our pharmacies) primarily to trading companies throughout China. We also planted ginkgo trees but have not incurred sales in the six months ended September 30, 2024.
Results of Operations
Comparison of the six months ended September 30, 2024 and 2023
The following table summarizes our results of operations for the six months ended September 30, 2024 and 2023:
| Six months ended September 30, | ||||||||||||||||
| 2024 | 2023 | |||||||||||||||
| Amount | Percentage of total revenue |
Amount | Percentage of total revenue |
|||||||||||||
| Revenue | $ | 71,159,724 | 100.0 | % | $ | 78,574,409 | 100.0 | % | ||||||||
| Gross profit | $ | 14,597,432 | 20.5 | % | $ | 15,933,089 | 20.3 | % | ||||||||
| Selling expenses | $ | 14,103,893 | 19.8 | % | $ | 14,044,750 | 17.9 | % | ||||||||
| General and administrative expenses | $ | 2,716,269 | 3.8 | % | $ | 1,632,357 | 2.1 | % | ||||||||
| Loss from operations | $ | (2,222,730 | ) | (3.1 | )% | $ | 255,982 | 0.3 | % | |||||||
| Other Income (expenses), net | $ | (43,763 | ) | (0.1 | )% | $ | (1,141,071 | ) | (1.5 | )% | ||||||
| Income tax expense | $ | 10,599 | 0.0 | % | $ | 39,172 | 0.0 | % | ||||||||
| Net loss | $ | (2,277,092 | ) | (3.2 | )% | $ | (924,261 | ) | (1.2 | )% | ||||||
Revenue
Primarily due to the decrement in our wholesale business, revenue decreased by $7,414,685 or 9.4% for the six months ended September 30, 2024, as compared to the six months ended September 30, 2023.
Revenue by Segment
The following table breaks down the revenue of our four business segments for the six months ended September 30, 2024 and 2023:
| For the six months ended September 30, | ||||||||||||||||||||||||
| 2024 | 2023 | |||||||||||||||||||||||
| Amount | % of total revenue |
Amount | % of total revenue |
Variance by amount |
% of change |
|||||||||||||||||||
| Revenue from retail drugstores | $ | 37,734,640 | 53.0 | % | $ | 36,644,373 | 46.6 | % | $ | 1,090,267 | 3.0 | % | ||||||||||||
| Revenue from online sales | 14,322,981 | 20.2 | % | 15,899,743 | 20.2 | % | (1,576,762 | ) | (9.9 | )% | ||||||||||||||
| Revenue from wholesale business | 19,102,103 | 26.8 | % | 26,030,293 | 33.2 | % | (6,928,190 | ) | (26.6 | )% | ||||||||||||||
| Revenue from farming business | - | - | % | - | - | % | - | - | % | |||||||||||||||
| Total revenue | $ | 71,159,724 | 100.0 | % | $ | 78,574,409 | 100.0 | % | $ | (7,414,685 | ) | (9.4 | )% | |||||||||||
Retail drugstores sales, which accounted for approximately 53.0% of total revenue for the six months ended September 30, 2024, increased by $1,090,267, or 3.0% compared to the six months ended September 30, 2023 to $37,734,640. However, excluding the impact of exchange rate fluctuation, the actual retail drugstores sales increased 4.0%. Sales from pre-existing stores increased by approximately $580,538, or 1.6%, while new stores contributed approximately $509,729 in revenue in the six months ended September 30, 2024.
The actual increase in our retail drugstore sales is primarily due to continuous adjustments of merchandises, suitable to the market and improved store employee incentive plan, and contribution from the new store sales. The series of marketing strategies we launched in 2024, such as local community sales events and the membership care program, also contributed to the increase in retail drugstore sales. In the future, we expect our retail drugstores sales will continue to grow.
Our new store has contributed additional sales. Our store count is 132 as of September 30, 2024 and 128 as of September 30, 2023.
Our online pharmacy sales decreased by approximately $1,576,762, or 9.9% for the six months ended September 30, 2024, as compared to the six months ended September 30, 2023. The decrease was primarily caused by a decrease in sales via e-commerce platforms such as JD and Pinduoduo. Because the online prices are transparent, to be competitive in online sales, we have to keep low prices. More competitors came into the online retail sales market. As we do not have dominating power such as lowest prices or exclusive products, we may not be able to improve our online pharmacy sales significantly in the near future.
Wholesale revenue decreased by $6,928,190 or 26.6%. As a local wholesale distributor in pharmaceutical products, our sales are limited to local and neighborhood regions. As the market became competitive, to keep reasonable profitability, we abandoned certain wholesales with low gross profit margin in the six months ended September 30, 2024. As a result, the wholesale revenue declined. However, in recent years, online platforms such as Pharmacist Help, Yiyao Help and Yao Help have become popular ways to transact medical products by bulk. The new online platforms provide us with access to potential vendors, clinics, pharmacies across the country. Additionally, although the prices of certain products may not be competitive in our region, they may be attractive in other jurisdictions such as inland counties and villages nationwide. Moreover, if we are able to increase our sales volume by selling more products via the platforms, we could have stronger power to negotiate with our suppliers and obtain more discounts. Therefore, we believe that selling on the modern wholesale platform may be a new growth opportunity. Therefore, we are actively looking for potential acquisition targets with trading on the platforms or their own trading platforms to strengthen our wholesale business.
For the six months ended September 30, 2024 and 2023, we had not generated revenue from our farming business. We planted ginkgo and maidenhair trees starting from the year ended March 31, 2013, more than ten years ago. A ginkgo tree may have a growth period of up to twenty years before it is mature enough for harvest. Usually, the longer it grows, the more valuable it becomes. We plan to continue cultivating the trees in order to maximize their market value in the future.
Gross Profit
Gross profit decreased by $1,335,657 or 8.4% period over period primarily as a result of a decrease in gross profit provided by retail drugstores and wholesale business, which experienced decrease for the six months ended September 30, 2024. At the same time, gross margin increased from 20.3% to 20.5%. The average gross margins for each of our four business segments are as follows:
| For the six months ended September 30, |
||||||||
| 2024 | 2023 | |||||||
| Average gross margin for retail drugstores | 29.3 | % | 31.4 | % | ||||
| Average gross margin for online sales | 11.0 | % | 11.0 | % | ||||
| Average gross margin for wholesale business | 10.4 | % | 10.3 | % | ||||
Retail gross margins decreased. In order to control its budget, the local municipal health insurance agency adjusted down certain prices of drugs reimbursed by it from time to time. We actively negotiated with suppliers to lower the purchase price as well, so we can keep reasonable profit margin. However, certain pharmaceutical giant companies are not willing to lower their prices. On the other side, as overall drugstore market becomes more competitive, we had to lower our prices to keep our market shares. Unless the economy quickly recovers, we do not expect to keep a high retail profit margin.
Gross margin of online pharmacy sales varied slightly. Due to online price transparency, customers can easily compare prices between different online pharmaceutical vendors. In order to attract customers, we are unable to raise sales prices significantly. On the other side, we continuously searched for popular products with high profit margin and negotiated with the suppliers for better terms. As a result, our profit margin for online sales kept stable.
Wholesale gross margin increased primarily due to various products with different profit margins we carried and sold to certain pharmaceutical vendors. Although as a retailer and distributor we have attempted to market the products to major local hospitals and other pharmacies, we have not been able to make significant progress. As a result, we don’t have big bargain power on the prices. So our wholesale profit margin varies from time to time. Until we are able to obtain status as a provincial or national exclusive sale agent for certain popular drugs or have sales access to large local hospitals, we may have to maintain low profit margins in order to drive sales on our wholesale business.
Selling and Marketing Expenses
Selling and marketing expenses increased by $59,143 or 0.4%, as compared to the same period of last fiscal year, primarily due to increase in rent due to the opening of several new stores, offset by decrease in labor fee. In responses to the government insurance budget control, we also cut off or combine certain administration staff. Overall, such expenses as a percentage of our revenue were 19.8% and 17.9% respectively, for the six months ended September 30, 2024 and 2023.
General and Administrative Expenses
General and administrative expenses increased by $1,083,912 or 66.4%, as compared to the same period of last year, primarily due to the increase in bad debt expense. For the six months ended September 30, 2024, we reversed bad debt allowance of $0.2 million as compared to reversal of bad debt allowance of $0.9 million in the six months ended September 30, 2023. As a result, the reversal of bad debt allowance decreased by approximately $0.8 million. Such expenses as a percentage of revenue increased to 3.8% from 2.1% for the same period of last year.
Investment Loss
Investment loss for the six months ended September 30, 2024 is nil, decreased by $1,642,910, or 100%, as compared to $1,642,910 the same period of last fiscal year. The loss is related to the Company’s investment in Zhejiang Zhuoli Life Service Co., LTD (“Zhuoli Service”), formerly known as Zhejiang Zhetong Medical Co., Ltd., a company established in March 2020, and mainly focusing on the potential acquisitions or the cooperation with local pharmacies. Zhuoli Service has incurred expense in developing business such as searching for store locations, local store chains and business expansion opportunities since our investment. As a result, such loss was recorded as investment loss for the six months ended September 30, 2023. As of March 31, 2024, the carrying amount of Zhuoli Service was nil.
(Loss) Income from Operations
As a result of the above, we had loss from operations of $2,222,730 for the six months ended September 30, 2024, as compared to income from operations of $255,982 a year ago. Our operating margin for the six months ended September 30, 2024 and 2023 was (3.1)% and 0.3%, respectively.
Income Taxes
Our income tax expense decreased by $28,573 period over period due to a decrease in overall profit.
Net Loss
As a result of the foregoing, net loss is $2,277,092 for the six months ended September 30, 2024 as compared to a net loss of $924,261 for the six months ended September 30, 2023.
Liquidity and Capital Resources
Our cash flows for the periods indicated are as follows:
| For the six months ended September 30, |
||||||||
| 2024 | 2023 | |||||||
| Net cash (used in) provided by operating activities | $ | (9,954,817 | ) | $ | 722,702 | |||
| Net cash (used in) investing activities | $ | (430,286 | ) | $ | (1,325,618 | ) | ||
| Net cash provided by financing activities | $ | 7,828,037 | $ | 327,923 | ||||
For the six months ended September 30, 2024, net cash used in operating activities amounted to $9,954,817, as compared to $722,702 net cash provided by operating activities for the same period a year ago. The change is primarily attributable to an increase of $3,317,679 in amortization of right-of-use assets, an increase of $3,980,374 in accounts receivable, and an increase in inventories and biological assets of $3,298,158 offset by a decrease in operating lease liabilities of $2,921,133, a decrease in loss from long-term investments of $1,642,910, a decrease in accounts payable of $14,371,651 and a decrease in accrued expenses and other liabilities of $1,459,611.
For the six months ended September 30, 2024, net cash used in investing activities amounted to $(430,286), as compared to $(1,325,618) for the same period a year ago. The change is primarily attributable to an increase in investment in a joint venture of $1,122,224 offset by a decrease in purchase of property and equipment of $145,179 and a decrease in additions to leasehold improvements of $108,701.
For the six months ended September 30, 2024, net cash provided by financing activities amounted to $7,828,037, as compared to $327,923 net cash provided by financing activities for the same period a year ago. The change is primarily due to proceeds from notes payable, repayment of notes payable, and proceeds from equity and debt financing.
As of September 30, 2024, we had cash of approximately $31,092,907. Our total current assets as of September 30, 2024, were $71,081,644 and total current liabilities were $67,537,401, which resulted in a working capital of $3,544,243.
SUBSEQUENT EVENTS
In October 2024, Mr. Lei Liu, our Chief Executive Officer, agreed to surrender for no consideration in total 52,500 fully-paid ordinary shares, par value $0.24 per share, of the Company (the “Ordinary Shares”), and Mr. Ming Zhao, our Chief Financial Officer, agreed to surrender for no consideration in total 2,500 Ordinary Shares, such Ordinary Shares in each case to be immediately cancelled by the Company.
In November 2024, Mr. Lei Liu, our Chief Executive Officer, agreed to surrender for no consideration in total 420,715 fully-paid Ordinary Shares, to be immediately canceled by the Company (collectively, the “Share Surrender”).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Date: January 15, 2025 | CHINA JO-JO DRUGSTORES, INC. | |
| By: | /s/ Lei Liu | |
| Name: | Lei Liu | |
| Title: | Chief Executive Officer | |